Patents by Inventor Ewa Wajs

Ewa Wajs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ESKETAMINE FOR THE TREATMENT OF DEPRESSION
    Publication number: 20240000728
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 4, 2024
    Inventors: Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
  • Esketamine for the treatment of depression
    Patent number: 11707440
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: July 25, 2023
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
  • ESKETAMINE FOR THE TREATMENT OF DEPRESSION
    Publication number: 20210386688
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 16, 2021
    Inventors: Carla Canuso, Wayne Drevets, Honglan Li, David Wood Hough, Adam Janik, Rachel Ochs-Ross, Jaskaran Singh, Ewa Wajs, Peter Zannikos